Final APPRAISE-al: Trial Report Argues Against Anticoagulant/Antiplatelet Combos In ACS
This article was originally published in The Pink Sheet Daily
Executive Summary
NEJM article points to much higher bleeding with no compensatory efficacy in failed APPRAISE-2 add-on trial with apixaban.
You may also be interested in...
Xarelto Review Sparks Debate Over Feasibility Of A Three-Drug ACS Regimen
While the focus of the Cardiovascular and Renal Drugs Advisory Committee’s meeting was on rivaroxaban’s use in treating acute coronary syndromes, some panelists questioned the wisdom of adding an antithrombin to current dual-antiplatelet therapy standard of care. The lack of data on rivaroxaban’s use with the two newest antiplatelet agents, prasugrel and ticagrelor, also could prove problematic from a labeling perspective due to theoretical concerns about increased bleeding.
Xarelto's Efficacy Impresses In ACS, But Bleeding Risk Will Complicate Approval
Bayer/Johnson & Johnson's rivaroxaban demonstrated a significant reduction in the risk of major adverse cardiovascular events, but it also significantly increased the risk of major bleeding in the Phase III ATLAS trial of acute coronary syndrome patients.
Xarelto's Efficacy Impresses In ACS, But Bleeding Risk Will Complicate Approval
Bayer/Johnson & Johnson's rivaroxaban demonstrated a significant reduction in the risk of major adverse cardiovascular events, but it also significantly increased the risk of major bleeding in the Phase III ATLAS trial of acute coronary syndrome patients.